Strokeg · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEc · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityg · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
1 finding from 1 review
Strokei · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in strokei compared with placebo (low certainty).
1 finding from 1 review
Myocardial infarction · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in myocardial infarction compared with placebo (low certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEb · patients with unprovoked venous thromboembolism
VTE extended prophylaxis probably leads to lower recurrent VTEb compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy · women with gestational diabetes mellitus
Metformin showed no clear difference in hypertensive disorders of pregnancy compared with glibenclamide ‐ maternal outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women with gestational diabetes mellitus
Metformin showed no clear difference in caesarean section compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Development of type 2 diabetes ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perineal trauma · women with gestational diabetes mellitus
Metformin showed no clear difference in perineal trauma compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Return to pre‐pregnancy weight ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postnatal depression ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · women with gestational diabetes mellitus
Metformin showed no clear difference in induction of labour compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Large‐for‐gestational age · Infants of women diagnosed with gestational diabetes
Metformin showed no clear difference in large‐for‐gestational age compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Perinatal mortality · Infants of women diagnosed with gestational diabetes
It is very uncertain whether metformin changes perinatal mortality compared with glibenclamide ‐ neonatal outcomes (very low certainty).
1 finding from 1 review
Death or serious morbidity composite · Infants of women diagnosed with gestational diabetes
Metformin may leads to lower death or serious morbidity composite compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review